Pfizer Inc.’s bivalent vaccine bolstered protective antibodies against the dominant omicron strains substantially more than its original booster in people older than 55, according to a compan…
By Robert Langreth | Bloomberg
Pfizer and German vaccine partner BioNTech SE compared blood samples from 36 people older than 55 who had received the bivalent booster with those from a control group of people over 55 who had received a fourth dose of the original shot. One month later, antibody levels against the widespread BA.4 and BA.
Pfizer’s own study, however, suggests that the bivalent shot “may induce a higher level of protection against the omicron BA.4 and BA.5 sublineages than the original vaccine,” the company said in its statement. The drugmaker has shared its results with the US Food and Drug Administration and said it plans to give them to regulators elsewhere soon.
Argentina Últimas Noticias, Argentina Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
New RSV vaccine given in pregnancy protects newborns from illness, Pfizer saysThe drugmaker Pfizer announced positive trial results for its RSV vaccine designed to protect newborns.
Leer más »
RSV Vaccine Given During Pregnancy Protects Newborns: PfizerNew trial data from Pfizer shows promising results of a vaccine given to mothers during pregnancy that later protects infants in their first months from the worst effects RSV. MedTwitter
Leer más »
WSJ News Exclusive | General Mills, Audi and Pfizer Join Growing List of Companies Pausing Twitter AdsA growing list of brands have paused their Twitter ads since Elon Musk's takeover, including General Mills, Audi and Pfizer, people familiar with the matter say
Leer más »
Pfizer, BioNTech start COVID-flu combination vaccine studyU.S. drugmaker Pfizer Inc and its German partner BioNTech SE have started an early-stage study to evaluate a combination vaccine targeting COVID-19 and influenza, the companies said on Thursday.
Leer más »